Necrostatin 1

Lipofectamine RNAiMAX reagent and Opti-MEM medium were obtained from Invitrogen (Carlsbad, CA, U.S.A.). RSL3 was purchased from Selleckchem (Houston, TX, U.S.A.). The mouse monoclonal antibody against β-actin, the rabbit polyclonal antibody against ACSL6 (SAB4500971), NaAsO₂, heptadecanoyl CoA (17:0-CoA), and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0/14:0 phosphatidylcholine (PC)), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (14:0/14:0 PE), and 1,2-dimyristoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (14:0/14:0 phosphatidylglycerol), were obtained from Sigma–Aldrich (St. Louis, MO, U.S.A.). The rabbit monoclonal antibody against ACSL4 (FACL4: ab155282) and the rabbit polyclonal antibody against ACSL5 (ab104892) were acquired from Abcam (Cambridge, MA, U.S.A.). Ferrostatin-1 was obtained from Cayman Chemicals (Ann Arbor, MI, U.S.A.). Necrostatin-1 was acquired from ChemScene LLC (Monmouth Junction, NJ, U.S.A.). CdCl₂ was purchased from Wako Chemicals (Osaka, Japan). The rabbit polyclonal antibody against ACSL1 (H-65), the mouse monoclonal antibody against ACSL3 (H-9), and DPQ were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Z-VAD-FMK (z-VAD) was obtained from the Peptide Institute, Inc. (Osaka, Japan).